DeepMed Research

Idorsia Ltd

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Subsidiary

Employees: -

Market Cap: $464M

Website: http://www.idorsia.com

Clinical Trials

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Setipiprant
Drug: Placebo

First Posted Date: 2010-10-21

Last Posted Date: 2018-07-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 438

Registration Number: NCT01225315

Locations: 🇵🇱
Clinical Investigative Site # 5501, Lodz, Poland
🇺🇸
Clinical Investigative Site # 6215, New Orleans, Louisiana, United States
🇺🇸
Clinical Investigative Site 6202, Knoxville, Tennessee, United States

and more 94 locations

Tezosentan in Patients With Pulmonary Arterial Hypertension

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: ACT-050089
Other: Placebo

First Posted Date: 2010-03-26

Last Posted Date: 2018-07-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 2

Registration Number: NCT01094067

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇯🇵
National Cardiovascular Center, Osaka, Japan
🇫🇷
Hopital Antoine Beclere, Clamart, France

and more 2 locations

Tezosentan in Pulmonary Arterial Hypertension

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Tezosentan

First Posted Date: 2010-03-01

Last Posted Date: 2018-07-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 3

Registration Number: NCT01077297

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇫🇷
Hopital Antoine Béclère, Paris, Clamart, France

and more 2 locations

Clazosentan in Aneurysmal Subarachnoid Hemorrhage

Phase 3

Terminated

Conditions: Aneurysmal Subarachnoid Hemorrhage

Interventions: Drug: Placebo
Drug: Clazosentan 5 m/h
Drug: Clazosentan 15 mg/h

First Posted Date: 2009-07-15

Last Posted Date: 2018-07-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 577

Registration Number: NCT00940095

Locations: 🇺🇸
Stanford Hospital and Clinis, Stanford, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 141 locations

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

Phase 3

Completed

Conditions: Aneurysmal Subarachnoid Hemorrhage

Interventions: Drug: Placebo
Drug: Clazosentan

First Posted Date: 2007-11-14

Last Posted Date: 2020-02-17

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 1157

Registration Number: NCT00558311

Locations: 🇩🇪
Thechnical University-Klinikum rechts der Isar, Munich, Germany
🇺🇸
State University of New York at Stony Brook-Health Sciences Center, Stony Brook, New York, United States
🇺🇸
University of Cincinnati-Department of Neurosurgery, Cincinnati, Ohio, United States

and more 113 locations

Tezosentan in Acute Heart Failure

Phase 3

Completed

Conditions: Acute Heart Failure
Acute Decompensation of Chronic Heart Failure
New Onset of Heart Failure

Interventions: Drug: tezosentan

First Posted Date: 2007-09-06

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 735

Registration Number: NCT00525707

Locations: 🇨🇭
Cardio Centro Ticino, Servizio Cardiovasculare, Lugano, Switzerland
🇵🇱
Kategra I Klinika Kardiolgii AM, Wroclaw, Poland
🇺🇸
Denver VAMC, Denver, Colorado, United States

and more 32 locations

Tezosentan in the Treatment of Acute Heart Failure

Phase 3

Completed

Conditions: Acute Heart Failure
Acute Decompensation of Chronic Heart Failure
New Onset of Heart Failure

Interventions: Drug: placebo
Drug: tezosentan

First Posted Date: 2007-09-03

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 713

Registration Number: NCT00524433

Locations: 🇺🇸
Oracle Research, Huntsville, Alabama, United States
🇺🇸
USC Medical Center, Los Angeles, California, United States
🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States

and more 39 locations

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

Phase 3

Terminated

Conditions: Hypertension, Pulmonary
Heart Diseases

Interventions: Drug: placebo
Drug: tezosentan

First Posted Date: 2007-04-10

Last Posted Date: 2018-07-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 274

Registration Number: NCT00458276

Locations: 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦
London Health Sciences Centre-University Hospital, London, Ontario, Canada
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 30 locations

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

Phase 2

Completed

Conditions: Aneurysmal Subarachnoid Hemorrhage

Interventions: Drug: Clazosentan 1 mg/h
Drug: Clazosentan 15 mg/h
Drug: Clazosentan 5 mg/h
Drug: Placebo

First Posted Date: 2005-05-18

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 413

Registration Number: NCT00111085

Locations: 🇺🇸
Dr. Aldrich, Baltimore, Maryland, United States
🇺🇸
Dr. Giuseppe Lanzino, Peoria, Illinois, United States
🇺🇸
Dr. Horner, Indianapolis, Indiana, United States

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy